2012 American College of Rheumatology guidelines for management of gout. Part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritis

February 2013
National Guideline Clearinghouse;2013, p141
No abstract available.


Related Articles

  • ACR Publishes Guidelines for Pharmacologic and Nonpharmacologic Treatment of Gout. DEVITT, MICHAEL // American Family Physician;9/15/2013, Vol. 88 Issue 6, p410 

    The article discusses guidelines published by the American College of Rheumatology for pharmacologic and nonpharmacologic treatment of gout. The guidelines cover urate-lowering therapy, analgesic and anti-inflammatory management of acute gouty arthritis. Physicians are advised to regularly...

  • ACR releases new guidelines for gout.  // PharmacoEconomics & Outcomes News;11/10/2012, Issue 666, p2 

    The article discusses the new guidelines for gout and gouty arthritis treatment released by the American College of Rheumatology (ACR) that was published in the October 2012 issue of "Arthritis Care & Research" recommending a first-line therapy with either febuxostat or allopurinol.

  • Managing gout: There's more we can do. Mead, Tatum; Arabindoo, Kavitha; Smith, Brianna // Journal of Family Practice;Dec2014, Vol. 63 Issue 12, p707 

    The article focuses on how to manage acute and chronic gout arthritis based on the guidelines of the American College of Rheumatology. Topics include the symptoms and risk factors associated with gout like cardiovascular and metabolic conditions and acute onset of pain and inflammation of a...

  • Overview of the Management of Acute Gout and the Role of Adrenocorticotropic Hormone. Schlesinger, Naomi // Drugs;2008, Vol. 68 Issue 4, p407 

    It is important to distinguish between therapy used to reduce acute inflammation in gout and therapy used to manage hyperuricaemia in patients with chronic gouty arthritis. This article discusses treatments for acute gout, emphasizing the use of corticotrophin (adrenocorticotropic hormone;...

  • Efficacy of Colchicien Prophylaxis in Gout. YĆ¼, Ts'ai Fan; Gutman, Alexander B. // Annals of Internal Medicine;Aug61, Vol. 55 Issue 2, p179 

    Analyzes the efficacy of colchicine prophylaxis in gout. Natural history of recurrent acute gouty arthritis unmodified by colchicine; Prophylactic program; Side reactions; Limitations.

  • American College of Rheumatology issues management guidelines for arthritis of the hip and knee. Hochberg, M.C.; Altman, R.D. // American Family Physician;2/15/1996, Vol. 53 Issue 3, p985 

    Presents management guidelines for arthritis of the hip and knee from the American College of Rheumatology. Nonpharmacologic and pharmacologic therapy; Risk factors for medication; Contact information.

  • New guidelines help providers manage rheumatoid arthritis. Klink, Barbara // Drug Topics;8/19/96, Vol. 140 Issue 16, p47 

    Informs that the American College of Rheumatology has published guidelines for the management of rheumatoid arthritis and monitoring drug therapy for condition. Nonsteroidal anti-inflammatories (NSAIDS) as first line of treatment; Disease-modifying antirheumatic drugs (DMARDs) as second line of...

  • A Swollen knee. Usatine, Richard P.; Sacks, Ben; Sorci, Jonathan // Journal of Family Practice;Jan2003, Vol. 52 Issue 1, p53 

    This article presents a case study of acute gouty arthritis in a 52-year-old African American homeless man. Acute gout is predominantly a disease of the lower extremity and most cases are characterized by rapid onset of monoarticular arthritis resulting from deposition of urate crystals and a...

  • Overview of Hyperuricaemia and Gout. Masseoud, D.; Rott, K.; Liu-Bryan, R.; Agudelo, C. // Current Pharmaceutical Design;Nov2005, Vol. 11 Issue 32, p4117 

    In most mammals purine degradation ultimately leads to the formation of allantoin. Humans lack the enzyme uricase, which catalyzes the conversion of uric acid to allantoin. The resulting higher level of uric acid has been hypothesized to play a role as an antioxidant. Hyperuricaemia is usually...

  • Gout: overview and newer therapeutic developments.  // Formulary;Mar2010, Vol. 45 Issue 3, p84 

    Gout is a chronic, progressive disease that is increasing in prevalence, it results from the deposition of urate crystals caused by the overproduction or underexcretion of uric acid. The disease is often, but not always, associated with elevated serum uric acid levels. The phases of gout include...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics